P
Phillip F. Pierce Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
High Impact
Researcher
faculty
24 h-index
58 pubs
2,097 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Phillip F. Pierce studies pharmacological interventions for neuropathic pain, particularly diabetic peripheral neuropathic pain (DPNP). His recent publications include work on LX9211, an orally-administered, non-opioid AAK1 inhibitor, investigating its efficacy and safety in randomized, double-blind, placebo-controlled studies. He has also published research on pilavapadin, another oral, non-opioid AAK1 inhibitor for DPNP, within a Phase 2b dose-ranging study. Pierce's research network includes collaborators such as S. L. Bruce at Arkansas State University, with whom he has co-authored shared publications.
In addition to his work on pain management, Pierce has contributed to research on technology applications in health, including a reliability study for a phone application designed to assess pupillary light reflex. His scholarship metrics include an h-index of 24, with 58 total publications and 2,090 total citations, and he is recognized as a highly cited researcher. Pierce maintains an active lab website.
Metrics
- h-index: 24
- Publications: 58
- Citations: 2,097
Selected Publications
-
A Reliability Study for SOBER-EYE, A Pupillary Light Reflex Assessment Phone App (2025)
Collaboration Network
Top Collaborators
Rodica Pop‐Busui
Opexa Therapeutics (United States) (US)
5 shared publications
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- 103-OR: LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy—Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- 1876-LB: Pilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)—Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study
Craig Granowitz
Opexa Therapeutics (United States) (US)
5 shared publications
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- 103-OR: LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy—Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- 1876-LB: Pilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)—Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study
Suma Gopinathan
Opexa Therapeutics (United States) (US)
5 shared publications
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- 103-OR: LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy—Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- 1876-LB: Pilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)—Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study
Christine N. Sang
4 shared publications
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- 103-OR: LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy—Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
Franklin Sun
4 shared publications
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- 103-OR: LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy—Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
Phillip Banks
3 shared publications
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
PHILLIP L. BANKS
Opexa Therapeutics (United States) (US)
2 shared publications
- 103-OR: LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy—Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
- 1876-LB: Pilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)—Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study
Anand Patel
2 shared publications
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
ANAND PATEL
1 shared publication
- 103-OR: LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy—Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
Anand C. Patel
1 shared publication
- Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
S. L. Bruce
Arkansas State University
1 shared publication
In database
- A Reliability Study for SOBER-EYE, A Pupillary Light Reflex Assessment Phone App
James Kerr Love
1 shared publication
- A Reliability Study for SOBER-EYE, A Pupillary Light Reflex Assessment Phone App
MARQUETTE B. HARDIN
Opexa Therapeutics (United States) (US)
1 shared publication
- 1876-LB: Pilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)—Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study
Manon Girard
Opexa Therapeutics (United States) (US)
1 shared publication
- 1876-LB: Pilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)—Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study
Guillermo E. Umpierrez
Opexa Therapeutics (United States) (US)
1 shared publication
- 1876-LB: Pilavapadin, an Oral, Non-opioid, AAK1 Inhibitor for Diabetic Peripheral Neuropathic Pain (DPNP)—Results from a Phase 2b, Dose-Ranging, Randomized, Multicenter Study
Similar Researchers
Based on overlapping research topics
H. Kenneth Spencer
University of Arkansas for Medical Sciences
Anesthesia and Pain Management
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Eniya Beemarajan
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Bob Daripa
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Anesthesia and Pain Management
Pharmacological Effects and Toxicity Studies
Johnathan Goree
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Anesthesia and Pain Management
Metabolism and Genetic Disorders
Reece Mitchell
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Jarna Shah
University of Arkansas for Medical Sciences
Neurological disorders and treatments
Anesthesia and Pain Management
Technology Adoption and User Behaviour